Heron Therapeutics reports Q3 2026 revenue of $35.3M and agrees to asset sale to CorMedix Therapeutics.

Heron Therapeutics announced Q3 2026 net revenue of $35.3 million, with growth in its Acute Care products ZYNRELEF and APONVIE, while Oncology revenues declined. The company revealed a definitive agreement for CorMedix Therapeutics to acquire substantially all of Heron's assets, pending stockholder approval. Heron has withdrawn its full-year 2026 financial guidance and will not host a conference call for these results. The asset sale marks a significant strategic shift for Heron, impacting its future operations and product commercialization.

Heron Therapeutics shares on Pluang surged by 40.98% to USD 0.40 as of Nov 09, 2026 20:42 WIB, rebounding strongly from their 52-week low of USD 0.27 but still well below the 52-week high of USD 1.49. This sharp daily gain contrasts with the stock's longer-term range, highlighting significant volatility. The market cap stands at $54.17 million, reflecting the company's current valuation amid its strategic asset sale.